2019 Surgical Pathology Update Diagnostic Pearls for the Practicing Pathologist Vol. III

All activity participants are required to take a written or online test in order to be awarded credit. All course participants will also have the opportunity to critically evaluate the program as it relates to practice relevance and educational objectives.

AMA PRA Category 1 Credit(s)^TM for these programs may be claimed until January 31, 2022.
This CME activity was planned and produced by Educational Symposia, the leader in diagnostic imaging education since 1975.
This CME activity was planned and produced in accordance with the ACCME Essential Areas and Elements.

• Describe the most common well-differentiated lipomatous tumors and the major diagnostic criteria for separating them from one another.
• Identify the most common morphologic patterns seen in soft tissue tumors.
• Apply the most useful immunohistochemical and molecular diagnostic techniques in the evaluation of soft tissue tumors.
• Discuss updates in the most recent WHO classification of renal tumors.
• Restate common and uncommon diagnostic pitfalls in bladder pathology.
• Explain how to reliably utilize both morphology and immunohistochemistry to differentiate germ cell tumors from mimics.
• Identify the histologic features of select cutaneous fibrohistiocytic tumors.
• Recognize cutaneous adnexal tumors that are associated with hereditary cancer predisposition syndromes.
• Describe the most useful ancillary diagnostic tests to aid in the diagnosis of challenging melanocytic lesions.
• Discuss current clinicopathologic diagnostic criteria for Barrett esophagus.
• Recognize the appearance of several medications that can be identified on routine histology.
• Explain the most common forms of gastritis with emphasis on the autoimmune form.
• Restate the natural history and disease biology of ductal carcinoma in situ.
• Recognize cytomorphologic pitfalls encountered in interpreting cerebrospinal fluid.
• Describe mediastinal anatomy and cytology sampling techniques.
• Discuss the appropriate use of p16 immunohistochemistry and HPV RNA in situ hybridization.
• Explain the TCGA molecular classification system of endometrial carcinoma.
• Review the interpretative challenges that attend MMR immunohistochemistry and understand the clinical implications of loss in tumors of the gynecologic tract.

No special educational preparation is required for this CME activity